Depression treatment does not always follow a straight line. Someone may try one antidepressant, switch medications, adjust the dose, add therapy, and still feel as though very little has changed. According to the National Institute of Mental Health, an estimated 21 million U.S. adults experienced a major depressive episode in 2021, representing about 8.3% of the adult population. Research published in The Journal of Clinical Psychiatry has also estimated that roughly 30.9% of adults receiving medication for major depressive disorder met criteria for treatment-resistant depression.
For people who reach that point, Spravato may become part of the conversation. Then another practical question usually comes up: how will treatment be paid for?
Fortunately, insurance coverage for Spravato is available through many health plans. That does not mean every policy approves it automatically. Coverage often depends on previous treatments, diagnosis, authorization requirements, and where care is provided.
Is Spravato Covered by Insurance?
Is Spravato covered by insurance? In many cases, it can be.
Spravato is an FDA-approved form of esketamine used for certain adults with treatment-resistant depression. Because it is given in a supervised healthcare setting rather than taken home like a standard prescription, insurance billing can look a little different.
Some plans process Spravato through the pharmacy benefit. Others handle part or all of the treatment through the medical benefit.
That distinction can affect prior authorization, copays, coinsurance, and the patient’s final pocket cost.
Before assuming a plan includes treatment, it helps to verify the actual benefits attached to the policy. Two people may have the same insurance company but very different coverage because their employers, deductibles, networks, or plan designs are different.
What Insurance Companies Require
There is usually paperwork involved before treatment begins.
Insurance companies require documentation showing why Spravato is medically appropriate. For someone with treatment-resistant depression, that often means records of antidepressants that were previously tried, how long they were taken, the dosage, and whether symptoms improved.
The insurer may also request clinical notes supporting the diagnosis.
In many cases, prior authorization is required. The treatment center sends information to the insurance carrier, and a reviewer compares it with the plan’s medical-necessity guidelines.
Spravato also has special administration requirements. It must be provided in an appropriate healthcare setting under supervision because patients need observation after each dose.
A missing medication date or incomplete treatment record may sound minor, but it can hold up approval. Having an accurate medication history ready can make this part considerably easier.
What Is Spravato Used For?
“Treatment-resistant” sounds vague, but it has a real clinical meaning: depression that hasn’t improved after at least two adequate trials of different oral antidepressants, each given enough time and at a proper dose to actually work.
By the time someone reaches that point, they’ve usually cycled through more treatment options than they care to count. Spravato steps in here — not as a replacement for what’s already prescribed, but as an addition to it, aimed at breaking through where standard options stalled.
There’s a second approved use: adults with major depressive disorder experiencing suicidal ideation or behavior. Speed matters clinically in that scenario, not just for comfort. Reduced depressive symptoms within days, rather than weeks, can change how a crisis unfolds.
None of this makes Spravato a starting point. It’s what comes after other roads have already been tried.
What Are Spravato’s Side Effects?
No medication comes free of trade-offs, and Spravato is no exception — most patients notice at least one side effect during treatment.
Dissociation is the most common side effect. Patients describe it as feeling foggy, detached, or briefly disconnected from their surroundings. It’s unsettling the first time, but it typically fades before the two-hour observation window ends. Other things to expect:
Nausea and dizziness, especially in early sessions before the body adjusts.
A temporary rise in blood pressure, which is exactly why monitoring happens before and after every dose.
Drowsiness strong enough that driving yourself home afterward isn’t an option — plan for a ride.
Shortness of breath, uncommon but taken seriously by care teams watching for it.
Anxiety or general unease, often tangled up with the dissociative effects rather than the depression itself.
Give it a couple hours, and most of these symptoms ease off before you leave the clinic. Over the long term, research so far points to meaningful symptom improvement with Spravato when it’s administered under proper supervision, though studies tracking extended use are still ongoing.
Given the dissociation risk and the blood pressure concerns, the Food and Drug Administration (FDA) requires Spravato to carry a boxed warning and limits it to a restricted distribution program. There’s no take-home version — every session happens under a care team’s direct watch, full stop.
Esketamine vs. Ketamine: What’s the Difference?
They get used interchangeably in conversation, but esketamine and ketamine aren’t quite the same thing.
Ketamine, the original compound, gets used off-label for depression — typically as ketamine infusions delivered through an IV at specialty clinics. It’s never been approved by the FDA specifically for depression, though plenty of providers prescribe it off-label with decent results.
The esketamine nasal spray is a refined piece of that molecule, put through formal clinical trials and approved for this specific purpose. That approval history is part of why Spravato tends to be covered by insurance more often than ketamine infusions, which patients frequently pay for out of pocket since they fall outside standard FDA-approved use.
The administration process looks different too. Spravato is self-administered as a nasal spray under supervision. Ketamine infusions need an IV line and usually take somewhere around 30 minutes to an hour, depending on the clinic.
Which one’s “better” isn’t really a fair question — some patients do noticeably better on one than the other, and the right call usually comes down to medical history, what insurance will cover, and which option is actually available nearby.
A Path Forward for Treatment-Resistant Depression
Spravato won’t work for everyone, and it’s not a cure. But for someone who’s already exhausted the usual antidepressant lineup, it offers something genuinely different — a mechanism that sidesteps the serotonin-focused model most treatments have leaned on for years.
Scottsdale TMS works with patients navigating exactly this kind of decision. The care team here evaluates whether Spravato, ketamine therapy, or another route fits a person’s specific history and goals, because depression treatment rarely works as a one-size-fits-all plan. Matching the right approach to the right patient is often what separates another letdown from real progress.